



**LUMOS**  
DIAGNOSTICS

## ASX ANNOUNCEMENT

### Lumos and BARDA Partnership - Investor Briefing

**MELBOURNE, Australia 9 October 2024** – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to invite investors to an online briefing session on Friday, 11 October 2024, at 10.30am AEDT.

During the session, Lumos CEO and Managing Director, Doug Ward and Vice President of Medical Affairs, Annie Bell will further discuss the news (ASX: 3 October 2024) that Lumos and the U.S. Biomedical Advanced Research and Development Authority (BARDA) have partnered to support the coming FebriDx® CLIA waiver study and US FDA application. The discussion will also cover plans for the coming CLIA waiver study and the non-dilutive funding awarded to Lumos.

FebriDx is a rapid point-of-care respiratory test which delivers results in around 10 minutes from a fingerstick blood sample. In July 2023, the U.S. Food and Drug Administration cleared FebriDx to be marketed in the U.S. as an aid in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology. The test has been cleared for use by healthcare professionals with patients presenting in urgent care or emergency care settings and is intended to be used in conjunction with clinical signs and symptoms, including other clinical and laboratory findings, to evaluate patients for acute respiratory infection.

The partnership aims to expand authorized testing to CLIA waived, point of care settings, including U.S. physician offices, urgent care clinics, or other outpatient clinics, where empiric antibiotic prescription is a common practice.

#### Webinar details

Date and time: Friday, 11 October 2024 from 10:30am AEDT

Registration: Please register to attend the webinar using the following link. Once registered, an email confirmation will be sent confirming access details:

[https://us02web.zoom.us/webinar/register/WN\\_8ALMdvULSfWTMGM3hQNW\\_eA](https://us02web.zoom.us/webinar/register/WN_8ALMdvULSfWTMGM3hQNW_eA)

The Lumos team looks forward to welcoming those investors who can join on the day.

**-Ends-**

***This announcement has been approved by the Lumos Disclosure Committee.***

### **About Lumos Diagnostics**

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit [lumosdiagnostics.com](http://lumosdiagnostics.com).

### **Forward-Looking Statements**

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

#### **Lumos - Media Contact:**

Haley Chartres – Australia  
HACK Director  
[haley@hck.digital](mailto:haley@hck.digital)  
+61 423 139 163

#### **Lumos - Investor Contact:**

Jane Lowe  
Managing Director, IR Department  
[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)  
+61 411 117 774

#### **Lumos - Company Registered Office:**

Lumos Diagnostics Holdings Ltd  
Level 4, 100 Albert Rd  
South Melbourne, VIC 3205, Australia  
+61 3 9087 1598